PHILADELPHIA, Aug. 5, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) announced its financial results for the three months ended June 30, 2011. The net loss (including non-cash losses) for the period was approximately $2,294,000 or $(0.02) per share as compared to a net loss of $1,416,000 or $(0.01) per share for the same period in 2010. This increase in net loss of $878,000 in 2011 was primarily due to the quarterly fair value revaluation of the estimated liability related to certain redeemable warrants resulting in a non-cash gain of $643,000 in 2011 as compared to a larger non-cash gain of $2,260,000 in 2010.
